Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

被引：43

作者：

Boespflug, Amelie ^{[1
,2
,3
]}

Caramel, Julie ^{[3
]}

Dalle, Stephane ^{[1
,2
,3
]}

Thomas, Luc

机构：

[1] Hosp Civils Lyon, Dermatol Unit, Lyon, France

[2] Claude Bernard Lyon 1 Univ, Dept Med, Lyon, France

[3] Claude Bernard Lyon 1 Univ, Canc Res Ctr Lyon, CNRS 5286, INSERM 1052, Lyon, France

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2017年 / 9卷 / 07期

关键词：

NRAS-mutant melanoma; targeted therapies; metastatic melanoma; clinical trials; ORAL MEK INHIBITOR; PHASE-II TRIAL; PROTEIN TRANSFERASE INHIBITOR; UNRESECTABLE STAGE-III; IB DOSE-ESCALATION; MUTANT MELANOMA; THERAPEUTIC TARGET; TRAMETINIB GSK1120212; CLINICAL ACTIVITY; 1ST-LINE THERAPY;

D O I：

10.1177/1758834017708160

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15-25% of all metastatic melanoma patients. It currently does not have an approved targeted therapy. Metastatic patients receive immune-based therapies as first-line treatments, then cytotoxic chemotherapy like carboplatin/paclitaxel (C/P), dacarbazine (DTIC) or temozolomide (TMZ) as a second-line treatment. We will review current preclinical and clinical developments in NRAS-mutated melanoma, and analyze ongoing clinical trials that are evaluating the benefit of different targeted and immune-based therapies, either tested as single agents or in combination, in NRAS-mutant melanoma.

引用

页码：481 / 492

页数：12

共 103 条

[11] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[12] A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors [J].

Bedard, Philippe L. ;

Tabernero, Josep ;

Janku, Filip ;

Wainberg, Zev A. ;

Paz-Ares, Luis ;

Vansteenkiste, Johan ;

Van Cutsem, Eric ;

Perez-Garcia, Jose ;

Stathis, Anastasios ;

Britten, Carolyn D. ;

Le, Ngocdiep ;

Carter, Kirsten ;

Demanse, David ;

Csonka, Denes ;

Peters, Malte ;

Zubel, Angela ;

Nauwelaerts, Heidi ;

Sessa, Cristiana .

CLINICAL CANCER RESEARCH, 2015, 21 (04) :730-738

[13] Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development [J].

Blake, James F. ;

Burkard, Michael ;

Chan, Jocelyn ;

Chen, Huifen ;

Chou, Kang-Jye ;

Diaz, Dolores ;

Dudley, Danette A. ;

Gaudino, John J. ;

Gould, Stephen E. ;

Grina, Jonas ;

Hunsaker, Thomas ;

Liu, Lichuan ;

Martinson, Matthew ;

Moreno, David ;

Mueller, Lars ;

Orr, Christine ;

Pacheco, Patricia ;

Qin, Ann ;

Rasor, Kevin ;

Ren, Li ;

Robarse, Kirk ;

Shahidi-Latham, Sheerin ;

Stults, Jeffrey ;

Sullivan, Francis ;

Wang, Weiru ;

Yin, Jianping ;

Zhou, Aihe ;

Belvin, Marcia ;

Merchant, Mark ;

Moffat, John ;

Schwarz, Jacob B. .

JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (12) :5650-5660

[14] Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function [J].

Boni, Andrea ;

Cogdill, Alexandria P. ;

Dang, Ping ;

Udayakumar, Durga ;

Njauw, Ching-Ni Jenny ;

Sloss, Callum M. ;

Ferrone, Cristina R. ;

Flaherty, Keith T. ;

Lawrence, Donald P. ;

Fisher, David E. ;

Tsao, Hensin ;

Wargo, Jennifer A. .

CANCER RESEARCH, 2010, 70 (13) :5213-5219

[15] How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization [J].

Brock, Ethan J. ;

Ji, Kyungmin ;

Reiners, John J., Jr. ;

Mattingly, Raymond R. .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2016, 16 (05) :358-369

[16] Clinical Characteristics and Outcomes With Specific BRAF and NRAS Mutations in Patients With Metastatic Melanoma [J].

Bucheit, Amanda D. ;

Syklawer, Erica ;

Jakob, John A. ;

Bassett, Roland L., Jr. ;

Curry, Jonathan L. ;

Gershenwald, Jeffrey E. ;

Kim, Kevin B. ;

Hwu, Patrick ;

Lazar, Alexander J. ;

Davies, Michael A. .

CANCER, 2013, 119 (21) :3821-3829

[17] ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas [J].

Capparelli, Claudia ;

Rosenbaum, Sheera ;

Berman-Booty, Lisa D. ;

Salhi, Amel ;

Gaborit, Nadege ;

Zhan, Tingting ;

Chervoneva, Inna ;

Roszik, Jason ;

Woodman, Scott E. ;

Davies, Michael A. ;

Setiady, Yulius Y. ;

Osman, Iman ;

Yarden, Yosef ;

Aplin, Andrew E. .

CANCER RESEARCH, 2015, 75 (17) :3554-3567

[18] HUMAN GENOME CONTAINS 4 GENES HOMOLOGOUS TO TRANSFORMING GENES OF HARVEY AND KIRSTEN MURINE SARCOMA-VIRUSES [J].

CHANG, EH ;

GONDA, MA ;

ELLIS, RW ;

SCOLNICK, EM ;

LOWY, DR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (16) :4848-4852

[19] RaIB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival [J].

Chien, Yuchen ;

Kim, Sungchan ;

Bumeister, Ron ;

Loo, Yueh-Ming ;

Kwon, Sung Won ;

Johnson, Cynthia L. ;

Balakireva, Mirey G. ;

Romeo, Yves ;

Kopelovich, Levy ;

Gale, Michael, Jr. ;

Yeaman, Charles ;

Camonis, Jacques H. ;

Zhao, Yingming ;

White, Michael A. .

CELL, 2006, 127 (01) :157-170

[20] A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors [J].

Chow, Laura Q. M. ;

Eckhardt, S. Gail ;

O'Bryant, Cindy L. ;

Schultz, Mary Kay ;

Morrow, Mark ;

Grolnic, Stacy ;

Basche, Michele ;

Gore, Lia .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (04) :631-646

← 1 2 3 4 5 6 7 8 9 10 →